多黏菌素类药物肾毒性分子机制及保护措施研究进展
发布时间：2018-12-07 12:20
【摘要】：正近20年来,多重耐药革兰阴性细菌(MDRGNR)在全球范围内呈蔓延趋势,严重威胁动物及人类健康;又由于缺乏新的、较为有效的抗生素,使得多黏菌素类(包括多黏菌素B及黏菌素)药物在临床又重新得到重视和应用,并成为治疗MDRGNR感染的最佳选择,甚至是最后的防线~([1])。肾毒性是多黏菌素的主要临床副作用之一,发生率高达60%~([1,2])。越来越多的证据表明,当前临床推荐的
[Abstract]:In the past 20 years, the multidrug resistant gram-negative bacteria (MDRGNR) have been spreading all over the world, which is a serious threat to animal and human health. Due to the lack of new and effective antibiotics, polymyxins (including polymyxin B and myxin B) have been paid more attention and applied in clinic, and become the best choice for the treatment of MDRGNR infection. Even the last line of defense. Nephrotoxicity is one of the main clinical side effects of polymyxin. There is growing evidence that the current clinical recommendations
【作者单位】： 中国农业大学动物医学院;
【基金】：国家科技支撑计划(2015BAD11B03)
【分类号】：R96;S859.7
，
本文编号：2367194
[Abstract]:In the past 20 years, the multidrug resistant gram-negative bacteria (MDRGNR) have been spreading all over the world, which is a serious threat to animal and human health. Due to the lack of new and effective antibiotics, polymyxins (including polymyxin B and myxin B) have been paid more attention and applied in clinic, and become the best choice for the treatment of MDRGNR infection. Even the last line of defense. Nephrotoxicity is one of the main clinical side effects of polymyxin. There is growing evidence that the current clinical recommendations
【作者单位】： 中国农业大学动物医学院;
【基金】：国家科技支撑计划(2015BAD11B03)
【分类号】：R96;S859.7
，
本文编号：2367194
本文链接：https://www.wllwen.com/yixuelunwen/yiyaoxuelunwen/2367194.html
最近更新
教材专著
